Analysis

Eyepoint, Inc. (EYPT) Stock Analysis

Eyepoint, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to EYPT.

websiteEYPT/analysis/EYPT

Eyepoint, Inc.

Eyepoint, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to EYPT.

Stock profile

Ticker

EYPT

Asset type

Stock

Market cap

$1.14B

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Eyepoint, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • EYPT primary listing
  • A2QJRU
  • PV3B

Latest Eyepoint, Inc. news

EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of M...

– LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after – – Continued favorable safety profile observed in masked Phase 3

EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments

Phase 3 wet AMD trials, LUGANO and LUCIA, remain on track with topline data expected beginning mid-2026 –Phase 3 DME clinical trials, COMO and CAPRI, rapidly advancing with over...

EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026

WATERTOWN, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the ...

EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments

– Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 – – Patients dosed in both COMO and CAPRI Phase 3

EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema

– Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retinal disease markets – – Topline data for DURAVYU in DME

Research sections

Valuation

Review valuation context for Eyepoint, Inc..

Future growth

Review future growth context for Eyepoint, Inc..

Past performance

Review past performance context for Eyepoint, Inc..

Financial health

Review financial health context for Eyepoint, Inc..

Dividend

Review dividend context for Eyepoint, Inc..

Management

Review management context for Eyepoint, Inc..

Ownership

Review ownership context for Eyepoint, Inc..

Other information

Review other information context for Eyepoint, Inc..

Community

Review community context for Eyepoint, Inc..